Ad
related to: Novavax and Vaccines
Search results
Novavax failed to capitalize on fears surrounding mRNA vaccines, activist investor says
Market Watch· 2 weeks agovaccine-maker’s management, as it called for an overhaul of the company’s marketing strategy to...
Down 60% From Its 52-Week High, Is Novavax Stock a Buy?
Motley Fool via Yahoo Finance· 2 weeks agoNovavax continues to focus on COVID Novavax has an approved COVID-19 vaccine and it's bullish on a...
Who can get a Covid booster this spring and how can you book?
BBC via Yahoo News· 2 weeks agoThey are part of the body's normal immune response to vaccination, and tend to resolve within a day...
Activist investor blasts Novavax for not using mRNA fears to boost COVID-19 vaccine sales
Quartz· 1 week agoThe activist hedge fund Shah Capital blasted the leadership of Novavax for not leveraging concerns...
Better Buy: Bluebird Bio Vs. Novavax
Motley Fool via Yahoo Finance· 2 weeks agoSo, Novavax should continue recording some sales from its product. For this year, it expects revenue between $800 million and $1 billion. Novavax is...
Shah Capital proposes new directors for Novavax board By Investing.com
Investing.com· 2 weeks agoShah Capital, holding a 6.7% stake in vaccine developer Novavax Inc. (NASDAQ: NASDAQ:NVAX), today...
Novavax investor Shah Capital pushes for board shakeup
Reuters via AOL· 2 weeks ago(Reuters) -A top shareholder of COVID-19 vaccine maker Novavax on Monday said the company has been...
Novavax (NASDAQ:NVAX) Trading 3.5% Higher
ETF DAILY NEWS· 2 weeks agoNovavax, Inc. (NASDAQ:NVAX – Get Free Report)’s stock price traded up 3.5% during mid-day trading on Friday . The stock traded as high as $4.48 and last traded at $4.45. 1,149,644 ...
Raleigh hedge fund urges board shakeup at Novavax - Triangle Business Journal
The Business Journals· 1 week agoA Raleigh-based hedge fund is pushing for changes at a struggling vaccine developer. The investment...
Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Investor's Business Daily· 1 day agoThe company noted that it achieved 48% market share for Covid vaccines in the U.S. during the fall...